Table 2.
Congenital disorders and DeI in patients after anti-neoplastic treatment and in the control group
| Congenital disorders | PCH | CG | p |
|---|---|---|---|
| n/% | |||
| Enamel defects | 53/88.3 | 24/40.0 | 0.000* |
| opacities (DDE index: 1, 2, 5) | 34/56.6 | 19/32.3 | 0.006* |
| hypoplasia (DDE index: 3) | 7/11.6 | 1/1.6 | 0.001* |
| combination of lesions (DDE index: 6, 7) | 12/20 | 4/6.6 | 0.068 |
| Root resorption (D1 + D2 + D3) | 36/60.0 | 25/41.6 | 0.0450* |
| V-shaped | 18/30.00 | 0/0.0 | 0.0000* |
| Microdontia (D4) | 12/21.67 | 0/0.0 | 0.0003* |
| no tooth bud (D5) | 16/26.67 | 4/6.66 | 0.0035* |
| DeI > 0 | 45/75.00 | 2643.33/ | 0.0004* |
| DeI | mean ± SD | ||
| 12.48 ±13.16 | 2.24 ±3.84 | 0.0000* | |
| DeI component D1 + D2 + D3 | 5.65 ±6.92 | 1.81 ±3.03 | 0.0009* |
| Others | n/% | ||
| taurodontism | 12/20.00 | 3/5.00 | 0.0135* |
| mesiodens | 1/1.67 | 0/0.0 | 0.3254 |
| Dentinoma | 18/30.0 | 9/15.0 | 0.0505 |
| Impacted teeth | 6/10.00 | 2/3.33 | 0.1466 |
*
statistically significant differences; p ≤ 0.05